This overview focuses on the cognitive transition between normal aging and dementia. Numerous studies indicate that individuals who will go on to develop dementia show cognitive deficits many years before the time at which a clinical diagnosis could be rendered. The degree of preclinical impairment is remarkably similar for tasks assessing episodic memory, executive functioning, and perceptual speed, consistent with the view that multiple brain alterations occur prior to clinical disease onset. Although most research in this area has dealt with Alzheimer disease (AD), several recent reports indicate that the pattern of preclinical impairment is very similar in the second largest dementia disorder, vascular dementia (VaD). This is important because currently the possibility for interventions to postpone disease onset is greater in VaD than in AD. Despite pronounced preclinical cognitive deficits in dementia, the performance distributions between cases and controls are largely overlapping, hampering the ability to identify high-risk individuals. To alleviate this problem, future research should evaluate hybrid models for the prediction of dementia. In such models, multiple indicators of cognitive functioning should be included along with markers from other domains that have been linked to subsequent dementia (such as brain imaging, genetics, and lifestyle variables). To the extent that these categories of variables add unique variance, classification accuracy will increase and the overlap in performance scores between incident cases and controls will decrease, thereby enhancing clinical usefulness. This approach would also facilitate the examination of interactive effects among classes of preclinical markers. Can J Psychiatry 2008;53 (6) :354-360 will be diagnosed with dementia at follow-up assessment. The chief issue is whether these incident dementia cases differed from those who remained nondemented at follow-up already at baseline assessment. The answer to that question is unequivocally affirmative.
Thus preclinical cognitive deficits in AD have been documented for several years, perhaps even decades, before a clinical diagnosis of dementia may be rendered. Much of the interest in impaired cognition prior to the AD diagnosis has centred around episodic memory. 3 This form of memory deals with the conscious retrieval of information acquired at a certain time in a certain place (for example, recall of a list of words encountered in the laboratory). 4 A key reason for the focus on episodic memory in prodromal AD is that there is converging evidence from histopathology, 5,6 structural imaging, 7, 8 and functional imaging (for examples see Bäckman et al 9 and Grady et al 10 ) that the hippocampus and neigbouring regions (for example, entorhinal cortex) are affected early on in the disease process. Evidence from lesion studies 11 and functional imaging research 12 strongly implicate the hippocampal complex in episodic remembering.
In agreement with these assertions, there is pervasive support for the view that episodic memory, whether assessed with recall 13, 14 or recognition, 15, 16 is severely impaired many years before the AD diagnosis. At the same time, it is clear that preclinical deficits in AD are not restricted to episodic memory. Thus impaired performance during the preclinical period have been observed for tasks assessing executive functioning, 17 perceptual speed, 18 verbal ability, 19 visuospatial skill, 1 and attention. 20 Consistent with these patterns, preclinical deficits were documented for composite measures of cognitive ability 21 as well as for global indicators of cognitive functioning such as the Mini-Mental State Examination. 22
Metaanalytic Evidence
In a recent quantitative integration of this literature based on a total of 47 studies (1207 preclinical AD cases and 9097 controls), we examined potential differences across cognitive domains regarding the size of the preclinical impairment. 23 In this metaanalysis, we also investigated differences in degree of impairment as a function of age of dementia onset, length of follow-up interval, sampling method (population-based compared with convenience sample), and whether subjects were classified with cognitive deficits (for example, mild cognitive impairment) at baseline assessment. Finally, we were interested in whether task characteristics within the key domain of episodic memory (that is, immediate compared with delayed testing, recall compared with recognition, verbal compared with nonverbal materials) had an impact on the degree of preclinical impairment.
Several aspects of the data from this study should be highlighted. First, the effect sizes (expressed in Cohen's d, which is computed as the mean performance difference between cases and controls divided by the pooled standard deviation 24 ) were remarkably large (d > 1.0) and virtually identical for the domains of episodic memory, executive functioning, and perceptual speed, as well as for global cognitive functioning. Somewhat smaller, albeit sizeable, effect sizes (d . 0.7) were obtained for verbal ability, visuospatial skill, and attention, whereas no group differences were seen for measures of primary memory (the ability to repeat back small amounts of material, such as telephone numbers). The latter finding is expected considering the fact that this form of memory is well preserved even among early clinical AD patients. 25 Thus, from these data, it is clear that episodic memory does not have a unique status as an indicator of impending AD. Rather, the findings suggest that the preclinical phase is characterized by a rather generalized cognitive impairment. Given this pattern of findings, it is of interest to note that, although much of the neurobiological work in this area has targeted the medial-temporal lobe, evidence indicates that multiple brain structures and functions are affected long before the AD diagnosis.
Specifically, preclinical AD is associated with reductions of grey-matter volume, 26 decreased blood flow, 27 and reduced glucose metabolism 28 in neocortical areas, including the frontal, parietal, and temporal cortices. Further, an increased amyloid burden 29 as well as an increased number of neurofibrillary tangles 30 were observed throughout the neocortex many years before diagnosis. Individuals at risk for developing AD also exhibit reduced activation of specific parietal regions during semantic classification. 31 Finally, general alterations of brain function in preclinical AD were demonstrated, such as increases in white-matter hyperintensities, 32 and a reduction of whole-brain glucose use. 33 The obvious point, then, is that the generalized cognitive impairment in preclinical AD revealed in our metaanalysis 23 makes perfect sense considering the multifaceted and widespread brain alterations in these individuals.
This analysis also showed that the magnitude of cognitive impairment was somewhat larger for earlier-onset (aged <75 years) compared with later-onset (aged 75+ years) cases. This may reflect more severe brain lesions in earlier-onset individuals, 34 that the controls perform at lower levels in higher ages 35 restricting the room for further deterioration in preclinical AD, or both. A more obvious observation was that the size of the preclinical impairment was greater for shorter (about 2 years before diagnosis) than for longer (about 5 years before diagnosis) follow-up intervals. That said, it is of note that quite sizeable impairments (d . 1.0) were seen even in studies employing longer retest periods. Further, the degree of impairment generalized well across study samples (population-based, convenience) and participant status (nonclassified, classified with cognitive impairment). Finally, within the episodic memory category, delayed testing revealed larger effect sizes than immediate testing and recall yielded larger effect sizes than recognition. In turn, these results might reflect the fact that preclinical AD is associated with deficits in consolidation in memory, and retrieval problems may be present in preclinical AD, in addition to difficulties in encoding and consolidation.
Preclinical Cognitive Deficits in VaD
Comparatively little empirical attention has been directed at potential preclinical cognitive markers in VaD. This is an unfortunate omission, because many vascular risk factors (for example, hypertension) are amenable to treatment to a degree that is not true in AD. For several reasons, a preclinical phase with cognitive problems is to be expected also in VaD, and these problems may mimic those observed in preclinical AD. First, different forms of vascular alterations are known to affect cognition in the absence of dementia, including hypertension, atherosclerosis, diabetes, white-matter lesions, so-called silent strokes, and cardiovascular signs. 36 Thus, given that VaD develops through combined effects of different vascular mechanisms that affect cognitive performance, cognitive deficits may be observable before the condition reaches its clinical threshold. Second, autopsy evidence suggests that a sizeable proportion of patients diagnosed with AD or VaD exhibit brain pathology characteristic of the other disorder, and some degree of cerebrovascular pathology is present in almost all AD cases. 37, 38 Third, given that early clinical AD and VaD patients exhibit strikingly similar patterns of cognitive impairment, [39] [40] [41] similarities in preclinical manifestations may be expected as well.
Those studies that have addressed cognition before the VaD diagnosis demonstrate a rather consistent pattern, indicating preclinical cognitive deficits in VaD that resemble those observed in AD. Thus, both for global cognitive ability 42, 43 and for episodic memory, 44, 45 clear deficits have been reported among those who will be diagnosed with VaD years before diagnosis, and the size of these deficits is quite similar to that reported for preclinical AD. 36 In a series of studies, we have systematically compared preclinical VaD and AD patients regarding the timing and extent of preclinical cognitive deficits. In 2 studies, we compared cognitive functioning in preclinical VaD, preclinical AD, and normal controls 3 years before the dementia diagnosis. The VaD diagnosis was mainly a diagnosis of poststroke dementia (multiinfarct dementia or strategic single infarct). A key finding was that cognitive deficits were present 3 years before the diagnosis of VaD, both for a measure of global cognition 46 and for measures of episodic memory functioning. 47 Further, the pattern of cognitive deficits in preclinical VaD was similar to that observed in preclinical AD, and there were no significant differences in cognitive performance between the 2 dementia groups.
In Laukka et al, 47 a comprehensive cognitive test battery was administered. The general pattern indicated poorer cognitive performance for both preclinical dementia groups, compared with the controls. However, whereas the preclinical AD group performed worse than the controls on measures of episodic memory, verbal fluency, and visuospatial functioning, the preclinical VaD group showed deficits only on the episodic memory measures (word recall and recognition, and face recognition). These results suggest a somewhat more pronounced cognitive deficit in preclinical AD. However, again there were no reliable differences between the 2 dementia groups in any task, and both groups showed the most pronounced impairment in episodic memory.
Further, similar levels of impairment in AD and VaD 48, 49 were also demonstrated for a measure of global cognitive functioning 6 years before diagnosis. An exception to this pattern was observed in a study comparing the effect of preclinical dementia in 2 verbal fluency tasks. Although both preclinical dementia groups showed poorer performance on letter fluency (the ability to name as many words as possible beginning with a specified letter in a short time), the preclinical VaD individuals outperformed the preclinical AD individuals on category fluency (the ability to name as many exemplars of a category as possible in a short time) 3 years before diagnosis. 50 The finding that the preclinical AD individuals were disproportionately impaired in category fluency is in agreement with observations that the medialtemporal lobe is involved in this task. 51, 52 A possible reason for this is that the search process in a category fluency task (in this case supermarket fluency-the ability to rapidly name items found in a supermarket) invokes personal experiences and thus involves episodic memory retrieval. Given that the medial-temporal lobe is relatively more affected in preclinical AD, compared with VaD, 5,7 this might explain the larger category fluency impairment for the preclinical AD individuals.
Two points should be made regarding the generally similar patterns of preclinical cognitive impairment in VaD and AD. First, the relevant research largely involves VaD patients of the poststroke dementia type. The likelihood of observing differential patterns (for example, larger episodic memory impairment in preclinical AD and larger executive impairment in preclinical VaD) may be greater in VaD of subcortical origin. 36, 53 Second, the similar patterns observed in preclinical VaD and AD (for example, large episodic memory problems) do not necessarily imply alterations in similar neural circuitries. Episodic remembering draws on a large distributed network, including prefrontal and medial-temporal regions. 54 Alterations at any one location in this network may cause episodic memory impairment. To illustrate, a study comparing AD and subcortical stroke patients observed a double dissociation between memory dysfunction and regional glucose metabolic activity. Whereas performance on an episodic memory task correlated with left-hippocampal and middle-temporal gyrus metabolism in AD patients, it correlated with prefrontal lobe metabolism in patients with subcortical stroke. 55 Thus the same cognitive deficit may have different neurological underpinnings, depending on the etiology of the disorder.
Large Overlap Between Preclinical Cases and Controls
Although mean levels of cognitive performance differ markedly between preclinical dementia cases and controls many years before diagnosis, the performance distributions between these 2 groups overlap to a large degree. For example, in the metaanalysis on preclinical AD discussed above, 23 effect sizes larger than 1.0 were documented for episodic memory, executive functioning, and speed. Nevertheless, nearly one-half of the samples (preclinical AD, compared with controls) overlapped for these task domains. Although this is bad news from a clinical perspective (for example, regarding the possibility for early identification of specific individuals at risk), a pattern of overlapping distributions should be expected for at least 2 reasons. First, deficient cognitive functioning might have multiple origins in addition to being in a prodromal phase of dementia. These include demographic and social factors (such as low education, and low social and intellectual activity levels), but also psychiatric, metabolic, immunological, and hormonal disturbances. 3 As a result, some individuals who perform at low levels in cognitive tasks will be misclassified as at-risk individuals, despite the fact that they will not convert to clinical dementia during the follow-up period.
Conversely, individuals who will be diagnosed with AD vary, both in terms of onset of precipitous decline and in rate of change, during the preclinical period. 14, 56, 57 In particular, incident AD cases who exhibit relatively normal cognitive performance until shortly before follow-up, when decline occurs very rapidly, will be difficult to catch. Consistent with these observations, several studies demonstrate that individuals classified as cognitively impaired (with, for example, mild cognitive impairment, or with cognitive impairment, no dementia) differ greatly regarding future cognitive changes. [58] [59] [60] [61] For example, Palmer et al 60 
Trajectory of Preclinical Cognitive Decline
An unresolved issue of vital importance to the identification of at-risk individuals concerns the period during which precipitous decline occurs among those who will develop dementia. Although there is consensus that incident AD individuals show precipitous cognitive decline during the last 2 to 3 years before diagnosis, 13, 15, 49 evidence is mixed as to whether accelerated decline is observed longer before diagnosis. Stability of the magnitude of preclinical impairment from 6 to 3 years before diagnosis were observed for measures of episodic memory 13 and global cognitive ability 49 (see also Small and Bäckman 62 ) in AD and more recently also in VaD. 48 Similarly, Amieva and colleagues 63 reported differences between preclinical AD cases and controls on tests of memory and global cognitive ability 9 years prior to diagnosis, and that cognitive decline for the preclinical AD group began to accelerate around 3 years prior to diagnosis.
However, other evidence suggests that precipitous decline may occur in individuals who will be diagnosed with AD longer before diagnosis. In 2 studies 64,65 accelerated decline in episodic memory was demonstrated more than 5 years before diagnosis, although speeded measures of performance IQ exhibited accelerated decline around 2 years before diagnosis (see also Jorm et al 66 ) . Several factors may contribute to the equivocal findings, including the nature of the study sample. Specifically, it is conceivable that accelerated cognitive decline longer before diagnosis is more likely to be observed when strict selection criteria (for example, removal of individuals with other conditions that affect cognitive functioning) are employed. Moreover, the number of measurement points during the preclinical period may affect the probability of observing a nonlinear change function. Amieva et al 63 evaluated individuals annually over a 9-year period prior to diagnosis and applied sophisticated random-effects models to evaluate changes in functioning. This data-intensive design allows for a more detailed view into the nature of cognitive decline in preclinical AD. More information pertaining to this issue is critical to achieve a better understanding of the preclinical process in AD and VaD, and to improve early differentiation between cases and controls.
Avenues for Future Research
In the remainder of this article, I will highlight numerous research issues that, in my opinion, are vital for furthering our theoretical understanding of the transition from normal aging to dementia, as well in increasing the clinical utility of such research. As noted, despite the fact that mean cognitive scores of preclinical dementia cases and controls differ markedly years before diagnosis, the 2 groups still overlap to a considerable extent. That said, it should be noted that the metaanalytic evidence showing overlap scores around 50% was based on individual cognitive domains (for example, episodic memory). There is evidence that the identification of at-risk individuals increases greatly (with a concomitant decrease in overlap) when tasks assessing different cognitive domains (such as episodic memory, executive functioning, and semantic memory) are incorporated into the same prediction model. 1, 15 To minimize the overlap between cases and controls, future research should consider supplementing cognitive markers of incipient dementia with indicators from other domains that have been linked to dementia incidence. These include multiple measures of brain structure and function such as volumetric measures, 26, 67 glucose metabolism, 28, 33 blood flow, 27, 68 markers of amyloid deposition 29, 69 and neurofibrillary tangles, 30, 69 as well as white-matter alterations. 70, 71 Markers for genetic predisposition such as presence of the APOE-e4 allele, 72 subjective memory complaints, 61 family reports of cognitive impairment, 73 depressive symptoms, 74 as well as factors such as social isolation, 18 lack of intellectual engagement, 75 low physical activity levels, 76 and susceptibility to distress 77 should also be considered in this context.
In applying such hybrid models in identifying individuals at risk for developing dementia, the key issue is whether certain combinations of cognitive, biological, genetic, clinical, and social markers will increase prediction accuracy over and above what is achieved at the level of single categories of markers. Logically, improved differentiation will occur to the extent that the factors included contribute unique variance in group classification. Further, it will be of great interest to examine whether there are interactions between different classes of markers regarding the probability of a future dementia diagnosis. For example, could it be that an unfavourable situation regarding certain factors (such as carrying the APOE-e4 allele and having poor episodic memory) is offset by more favourable conditions for other factors (such as a rich social network and low amyloid burden)? Relatedly, will several unfavourable characteristics lead to increased cognitive decline and risk of dementia to a degree that is not predicted from an individual evaluation of the factors?
We also need more data pertaining to the trajectory of decline during the transition from preclinical to clinical dementia (for example, "Is the decline function linear over many years or does exacerbated loss occur only during the last few years preceding diagnosis?") 13, 64 An important issue related to this point concerns individual differences regarding rate of decline in preclinical dementia. Clinical observations suggest that some individuals show accelerated decline for only a short period before diagnosis, whereas others show gradual decline across a much longer period. However, in investigating factors that are systematically related to rate of cognitive change in preclinical dementia, negative findings have been documented for various factors, including age, sex, education, depression, APOE status, circulatory disease, vitamin-B deficiency, and social network. 56, 78, 79 Notably, many of these factors were implicated as risk factors for AD, or found to influence cognitive performance in normal aging. The negative findings might reflect the fact that the influence of individual-difference variables on cognitive performance is overshadowed by the emerging disease process itself. However, they could also be a function of the analytical methods employed (for example, analysis of variance or regression procedures). More recently developed analytical tools such as multilevel modelling may be more sensitive in identifying factors that share systematic relations with rate of cognitive change in preclinical dementia. If such relations were to be revealed, they would be extremely valuable in early identification of people destined to develop dementia.
The use of multilevel modelling will also permit addressing a fundamental issue regarding the development of AD and VaD, namely, whether a certain factor linked to the future occurrence of dementia (such as poor episodic memory, depressive symptoms, and low social activity levels) should be characterized as a risk factor or as an early marker. This constitutes a recurrent source of ambiguity in this field of research, for it is often difficult to differentiate between these possibilities. However, by using multiwave longitudinal data, it should be possible to determine the extent to which certain variables remain stable, increase, or decrease in importance as a function of time to diagnosis, regarding their relation to final dementia status. Thus by systematically examining whether different markers change in the strength of the association to dementia outcome as a function of time to diagnosis, more precise knowledge regarding the nature of dementia-related correlates will be obtained.
In summary, outstanding issues in future research on preclinical dementia include:
· evaluating multifactorial prediction models of incidence;
· delineating the point at which precipitous decline normally occurs during the preclinical period;
· assessing individual differences in rate of change from preclinical to clinical dementia; and · determining how the strength of the association between a certain factor and subsequent dementia varies as a function of time to diagnosis.
For all these research problems, it will be of great interest to elucidate differences and similarities concerning patterns of outcome between AD and VaD.
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